A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs AK 002 (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions
  • Sponsors Allakos
  • Most Recent Events

    • 05 Mar 2018 Results assessing pharmacodynamics and safety presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 05 Mar 2018 Results published in the Allakos Media Release
    • 05 Mar 2018 According to Allakos media release, positive results from this trial will be presented at the Joint Congress of the American Academy of Allergy Asthma and Immunology (AAAAI) and the World Allergy Organization (WAO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top